Literature DB >> 21504425

Molecular genetics of Dravet syndrome.

Peter De Jonghe1.   

Abstract

Before the advent of molecular genetics, the nature of Dravet syndrome remained largely obscure, and arguments in favour of either an acquired origin, such as the occurrence of Dravet syndrome after vaccination, or an inherited origin, such as the occurrence of epilepsy in relatives, were formulated. In 2001 we demonstrated that the majority of Dravet patients have a genetic cause due to loss-of-function mutations in the SCN1A gene. Understandably, since this syndrome severely affects reproductive fitness, these mutations almost exclusively arise de novo, with the rare exceptions of mosaic mutations in a non-affected transmitting parent. Besides classical Sanger sequencing, mutation analysis of the SCN1A gene also requires a method that allows the detection of genomic rearrangements (MAQ, MLPA), since microdeletions or whole gene deletions also result in Dravet syndromes. Depending on the series reported and their recruitment strategies, the yield of SCN1A mutations detected varied from 50 to 80%, implying that other genes or factors must be involved in these 'SCN1A-negative Dravet patients'. Recently mutations in some other genes have been described in these genuine Dravet patients who do not carry an SCN1A mutation. The second most important Dravet-associated gene is PCDH19.These patients initially may have all characteristics of Dravet syndrome but may later run a somewhat different course.
© 2011 The Author. Developmental Medicine & Child Neurology © 2011 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504425     DOI: 10.1111/j.1469-8749.2011.03965.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  17 in total

Review 1.  Genetics of epilepsy and relevance to current practice.

Authors:  Roberto Michelucci; Elena Pasini; Patrizia Riguzzi; Lilia Volpi; Emanuela Dazzo; Carlo Nobile
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 2.  Pathway-driven discovery of epilepsy genes.

Authors:  Jeffrey Noebels
Journal:  Nat Neurosci       Date:  2015-02-24       Impact factor: 24.884

3.  The GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome activated NMD and generated a truncated subunit that was partially rescued by aminoglycoside-induced stop codon read-through.

Authors:  Xuan Huang; Mengnan Tian; Ciria C Hernandez; Ningning Hu; Robert L Macdonald
Journal:  Neurobiol Dis       Date:  2012-06-30       Impact factor: 5.996

4.  Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study.

Authors:  Kenneth A Myers; Margot J Davey; Michael Ching; Colin Ellis; Bronwyn E Grinton; Annie Roten; Paul A Lightfoot; Ingrid E Scheffer
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

5.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

6.  Gene expression profiling in a mouse model of Dravet syndrome.

Authors:  Nicole A Hawkins; Jeffrey D Calhoun; Alexandra M Huffman; Jennifer A Kearney
Journal:  Exp Neurol       Date:  2018-10-19       Impact factor: 5.330

Review 7.  Epilepsy and mental retardation restricted to females: X-linked epileptic infantile encephalopathy of unusual inheritance.

Authors:  Kinga Duszyc; Iwona Terczynska; Dorota Hoffman-Zacharska
Journal:  J Appl Genet       Date:  2014-09-10       Impact factor: 3.240

Review 8.  Genome wide association studies (GWAS) and common forms of human epilepsy.

Authors:  Russell J Buono
Journal:  Epilepsy Behav       Date:  2013-07       Impact factor: 2.937

Review 9.  The Epilepsy Spectrum: Targeting Future Research Challenges.

Authors:  Gregory L Holmes; Jeffrey L Noebels
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 10.  The emerging agenda of stratified medicine in neurology.

Authors:  Paul M Matthews; Paul Edison; Olivia C Geraghty; Michael R Johnson
Journal:  Nat Rev Neurol       Date:  2013-12-10       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.